FONDAZIONE PER LA RICERCA FARMACOLOGICA GIANNI BENZI ONLUS

Promoting research in biological, medical and pharmaceutical areas in support of the development of innovative and safe medicines for everyone in Europe

PROVIDING METHODOLOGICAL SUPPORT TO THE BIOMEDICAL RESEARCH

Innovative study designs and research methods are crucial in the current framework for new effective drugs identification and development covering serious and unmet medical needs of special population

FOSTERING THE SCIENTIFIC PROGRESS ENSURING ETHICAL AND REGULATORY PRINCIPLES

Life science and new technologies’ advancements, such as Artificial Intelligence, are crucial to improve the patients’ life, however at the same time the highest level ethical rules have to be met and regulations continuously updated

PROMOTING ACCESS TO INNOVATIVE MEDICINES

Patients, including also those affected by rare diseases, are a relevant part of the research efforts and are entitled to have an easy and fast access to any scientific results that could improve their expectancy and quality of life

Encouraging the centrality of patients

Improving the patient involvement, in all the steps of the research and development process, can impact on patients' needs and disease outcomes. Raising awareness is a key point to engage patients and citizens in the healthcare field

ENHANCING THE USE OF DATA FOR THE SCIENTIFIC RESEARCH

Data Science application has a key role in the progress enhancement in pharmaceutical and health products field. Keeping pace with the progress require that all research data are Findable-Accessible-Interoperable-Reusable

fondazione per la ricerca farmacologica
gianni benzi onlus

Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus is a scientific research organisation, registered as a private, not-for-profit foundation in 2007, with the aim to promote research in biological, medical and pharmaceutical areas in Europe.

News

European Health Data Space Regulation: transforming healthcare

European Health Data Space Regulation: transforming healthcare

On 5 March 2025, the European Union officially published the European Health Data Space (EHDS) Regulation (Regulation (EU) 2025/327), marking a significant step towards a unified framework for electronic health data across member states.  The Regulation establishes a...

Have your say on rare diseases!

Have your say on rare diseases!

The Committee on Public Health (SANT) has launched a public consultation to gain a deeper understanding of the challenges faced by people living with rare diseases and to gather insights from those working in or involved with this field. Taking part is crucial as...

New EMA Guideline on Requirements for ATMPs in Clinical Trials

New EMA Guideline on Requirements for ATMPs in Clinical Trials

After two rounds of public consultations, the EMA adopted the Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials, which will enter into force on 1 July 2025. The guideline explains...

Analysis of paediatric post-authorization studies published in MDPI

Analysis of paediatric post-authorization studies published in MDPI

We are excited to announce a new publication on paediatric post-authorization studies (PASs). The study, authored by Annalisa Landi, Antonella Didio, Annunziata D’Ercole, Adriana Ceci, and Fedele Bonifazi is now available in MDPI Pediatric Reports. PASs play a crucial...

Stay updated on our activities

Sign up for our newsletter and follow us on social media

MEMBERSHIP

We collaborate with universities, institutions and research centers all over Europe with a unique goal: to foster and support the pharmacological, medical and biological research.

Subscribe To Our Newsletter

to keep you up to date on our activities and initiatives

La tua iscrizione non può essere convalidata.
La tua iscrizione è avvenuta correttamente.

We use Brevo as our marketing platform. By clicking below to submit this form, you are aware and accept that the information you have provided will be transferred to Brevo for treatment in accordance with their terms of use
Utilizziamo Brevo come nostra piattaforma di marketing. Cliccando qui sotto per inviare questo modulo, sei consapevole e accetti che le informazioni che hai fornito verranno trasferite a Brevo per il trattamento conformemente alle loro condizioni d'uso

You have Successfully Subscribed!